Key result
Background ARNI does not modify empagliflozin's effects on cardiac structure or LVESVI.
Why the study?
The influence of ongoing angiotensin receptor-neprilysin inhibitor treatment on the effect of empagliflozin on cardiac structure and function in HFrEF patients was unclear.
Does empagliflozin improve cardiac structure and function in patients with HFrEF regardless of background ARNI therapy?
RCT (n=190)
double-blind
randomized
Does empagliflozin improve cardiac structure and function in patients with HFrEF regardless of background ARNI therapy?
Empagliflozin's effects on cardiac structure and function in HFrEF are independent of background ARNI therapy.
Answers are grounded in this paper and cite their sources.
Empagliflozin effects on LV remodeling persist regardless of ARNI; extends RCT evidence supporting combination use in HFrEF.
The objective was to assess the effect of ongoing angiotensin receptor-neprilysin inhibitor(ARNI) on the effect of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) size and function in patients with heart failure and reduced ejection fraction(HFrEF). Post hoc analysis of the Empire HF trial, an investigator-initiated, double-blind, randomized controlled trial. 190 patients with HFrEF with New York Heart association class I-III symptoms with an ejection fraction of 40 % or below. Patients were stratified according to ongoing ARNI treatment at baseline. Empagliflozin 10 mg daily or placebo for 12 weeks. Echocardiography at baseline and follow-up. Left ventricular end-systolic volume index (LVESVI), end-diastolic volume index (LVEDVI), left atrial volume index (LAVI), left ventricular ejection fraction (LVEF). A total of 58 patients (31 %) received ARNI at baseline. Compared to with placebo, empagliflozin reduced the LVESVI ([−6.2 (−14.1 to 1.6); p = 0.12] and [−3.3 (−8.2 to 1.6); p = 0.19], interaction P = 0.49), LVEDVI ([−11.2 (−21.2 to −1.2); p = 0.03] and [−2.9 (−8.7 to 2.9); p = 0.32], interaction P = 0.13), and LAVI ([−3.9 (−9.1 to 1.2); p = 0.14] and. [−1.8 (−4.4 to 0.7); p = 0.16], respectively, interaction P = 0.9) in patients treated with and without ARNI at baseline, respectively. No treatment-by-ARNI subgroup interaction were found. Unaffected by baseline ARNI treatment, empagliflozin did not improve LVEF. The effect of empagliflozin on cardiac structure and function compared to placebo was not affected by background treatment with ARNI.
No takes yet. Share an insight, caveat, or question.
Larsen et al. (2023) conducted an RCT in chronic heart failure and a reduced ejection fraction (HFrEF) (n=190). Empagliflozin vs. placebo was evaluated on Change in left ventricular end-systolic volume index (LVESVI) in patients with baseline ARNI (MD -6.2, 95% CI -14.1 to 1.6, p=0.12). The effect of empagliflozin on cardiac structure and function, including LVESVI, was not modified by background ARNI treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: